IBI3011 / Innovent Biologics - LARVOL DELTA

A single-dose escalation study to evaluate the safety, tolerability and pharmacokinetic characteristics of the first human administration of IBI3011 (ChiCTR) - P1 | N=64 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University; Innovent Biologics (Suzhou) Co., Ltd.

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011 (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody (PRNewswire) - "This study is a single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 for the first-in-human administration, so as to support the subsequent clinical development of IBI3011. A total of 40 healthy volunteers and 24 patients with gout flares are planned to be enrolled."

Trial status • Gout

IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model (ACR Convergence 2025) - "The in vitro study has shown that IBI3011 inhibits the activation of IL1, IL33, and IL36 signaling pathway effectively through blocking the co-receptor IL1RAP. The preclinical mouse models have demonstrated that IBI3011 exerts a dose-dependent anti-inflammatory effect. These preclinical results underscore the potential of IBI3011 as a therapeutic candidate for autoimmune and inflammatory diseases."

Preclinical • Dermatology • Gout • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • IFNG • IL1A • IL1R1 • IL1RAP • IL33 • TNFA